Position in SVTRnew
Snapshot 2026-10-21- Startup SignalsRankedof 2,268
- Life SciencesRankedof 239
- AI for ScienceRankedof 97
- Drug DiscoveryRankedof 56
About
LattixOrigin builds DigitalBrain-M1, a cross-scale human brain foundation model trained on single-cell data from over 40 million brain cells, 15,000 donors and 26 neurological diseases, validated with human brain organoids, serving hospitals and pharma in neurodegenerative target discovery.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 4
Founders / team· 1
Founders / core team
Investors
Funding history
- 2026-10-20Seed近千万美元
Investors · Shunwei Capital, YM Capital, Xirius, Zhongguancun Capital
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- LattixOrigin
Cross-scale human brain foundation model for drug target discovery in neurodegenerative diseases
Seed · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- Network Bio
Links leading US academic biobanks into a unified research network producing training-ready multimodal datasets, and trains disease-specific AI foundation models on them that transfer across diseases, for disease detection, biomarker discovery and drug development
Undisclosed · $50M · 2026-08
$50M - Enveda Biosciences
Discovers naturally derived drugs from plants and microbes using its in-house AI foundation model PRISM; three oral drug candidates have entered clinical trials
Series D+ · $845M · 2026-09 · Valuation $2.0B
$845MValuation $2.0B - Ecotone
Genomic foundation model (diffusion transformer dnaSORA) that locates disease-causing DNA sequences in rare genetic diseases, for pharma and biotech drug discovery
—
China
BusinessLatest roundTotal raisedDate- Convergen
TRIM21-based TrimTAC targeted protein degradation platform for therapies clearing pathological protein aggregates; pipeline focused on neurodegenerative and autoimmune diseases
Seed · $25M · 2026-08
$25M - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - AIPher
AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs
Angel · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - OutSee
AI analysis of individual genomes to predict disease biology and help drug developers find new targets
Seed · $2M · 2025-06
$2M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Miles Wang 新公司
Develops AI models for drug discovery
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in North China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 4 in North China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 7 in North China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 2 at a nearby stage · 7 in North China
Request intro →HongShan
7 Life Sciences deals in the last 24 months · 5 at a nearby stage · 6 in North China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 4 at a nearby stage · 4 in North China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.